CLCatherine Lumley

Catherine Lumley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine Lumley has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Outcomes of Patients With pT1-T2N0 Oral Tongue Squamous Cell Carcinoma

    by Jessica M. Wilson, Catherine Lumley, Xianming Tan, Colette Shen, Andrew Coniglio, Mark Weissler, Wendell G. Md Yarbrough, Trevor Hackman, Jeffrey Blumberg, Adam Zanation, et al.

    Objective: The objective of this study was to evaluate the clinical outcomes in a cohort of patients with early-stage oral tongue squamous cell carcinoma (OTSCC). Materials and Methods: We conducted a retrospective analysis of patients with pT1-T2N0 (American Joint Committee on Cancer [AJCC] seventh edition) OTSCC treated from 2000 to 2018. Two-year actuarial rates of local regional control, cancer-specific survival, and overall survival were calculated for the entire cohort and patients with/without adjuvant radiation. Results: Ninety-six patients met the criteria with a median follow-up of 4 years; 14 had adjuvant radiation, while 82 had surgery alone. Two-year local regional control was 82.7% (75.4% to 90.8%) for the entire cohort, 84.9% (77.8% to 93.2%) for surgery only, and 70.7% (50.2% to 99.6%) for patients with adjuvant radiation. Two-year progression-free survival was 82.7% (75.3% to 90.8%). Of the 20 patients with recurrence, 11 (55%) were successfully salvaged. Conclusion: Local regional recurrence remains modest in early-stage OTSCC, but salvage is possible with high survival rates. Level of Evidence: Level III—retrospective cohort study.


  • Academic Affiliation and Surgical Volume Predict Survival in Head and Neck Cancer Patients Receiving Surgery

    by Douglas R. Farquhar, Maheer M. Masood, Nicholas R. Lenze, Siddharth Sheth, Samip N. Patel, Catherine Lumley, Adam M. Zanation, Mark C. Weissler, Andrew F. Olshan, Trevor G. Hackman

    Objective: To determine whether the academic affiliation or surgical volume affects the overall survival (OS) of human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC) patients receiving surgery.Methods: A retrospective study of 39 North Carolina Medical Centers was conducted. Treatment centers were classified as academic hospitals, community cancer centers, or community hospitals and were divided into thirds by volume. The primary outcome was 5‐year OS. Hazard ratios (HR) were determined using Cox proportional hazard models, adjusting for demographics, tumor site, stage, insurance status, tobacco use, alcohol use, stage, chemotherapy, and radiation therapy. Patients were also stratified by stage (early stage and advanced stage).Results: Patients treated at community cancer centers had significantly better 5‐year OS (HR 0.68, 95% confidence interval [CI] = 0.48–0.98), and patients treated at academic hospitals trended toward better 5‐year OS (HR 0.72, 95% CI = 0.50–1.04) compared to patients treated at community hospitals. The effect for academic affiliation on survival was more pronounced for patients with advanced stage cancer at diagnosis (HR 0.60, 95% CI = 0.37–0.95). There were no significant survival differences among early stage patients by treatment center type. Top‐third (HR = 0.64, 95% CI = 0.42–0.96) centers by surgical volume had significantly better 5‐year OS, and middle‐third (HR = 0.71, 95% CI = 0.51–1.03) centers by volume trended toward better 5‐year OS when compared to the bottom‐third centers by volume.Conclusion: Patients treated at academic hospitals, community cancer centers, and hospitals in the top third by case volume have favorable survival for HPV‐negative HNSCC. The effect for academic hospitals is most pronounced among advanced stage patients.Level of Evidence: 4 Laryngoscope, 131:E479–E488, 2021


  • Post‐diagnosis aspirin use and survival in veterans with head and neck cancer

    by Catherine J. Lumley, Thomas M. Kaffenberger, Sameer Desale, Eshetu Tefera, Chihun Jim Han, Hind Rafei, Jessica H. Maxwell

    Background: Our objective was to determine the effect of post‐diagnosis aspirin use on survival in veterans with head and neck squamous cell carcinoma.Methods: Retrospective cohort study of 584 veterans with head and neck squamous cell carcinoma treated at the Washington DC VA Medical Center between 1995 and 2015. Charts were queried for clinical‐pathologic data, aspirin prescriptions, and outcome. The Kaplan–Meier method was used to determine overall survival (OS) and disease‐specific survival (DSS) among aspirin users and nonusers.Results: A total of 329 patients met inclusion criteria. Primary subsites included oropharynx (n = 143), larynx (n = 105), oral cavity (n = 62), and hypopharynx (n = 19). Eighty‐four patients were aspirin users (25.5%). Aspirin users demonstrated significantly better 3‐year OS and DSS (78.6% and 88.1%) compared to nonaspirin users (OS: 55.9% and DSS: 70.2%; P = .0003 and P = .0019, respectively). On multivariate analysis, aspirin use remained independently associated with improved survival.Conclusion: Aspirin use following diagnosis and curative treatment of head and neck squamous cell carcinoma is associated with improved OS and DSS.